Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

PVRI Member Authors: Ardeschir Ghofrani, Marc Humbert, Michael Krowka


In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

Read the full article online


Pharmacology: Pharmacokinetics and Pharmacodynamics
Pulmonary Arterial Hypertension


Rodrigo Cartin-Ceba, Michael Halank, John Mattson, Arno Fritsch

Published in:

Pulmonary Circulation Vol 8: No 2 cover image

June 2018

Pulmonary Circulation Vol 8: No 2

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI